Skip to content

Association of seizure frequency and depressive symptoms in patients with epilepsy

Association of seizure frequency and depressive symptoms in patients with epilepsy - Mondy

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00031126
Enrollment
20
Registered
2023-03-13
Start date
2023-09-21
Completion date
Unknown
Last updated
2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diagnosed focal or generalized epilepsy with depressive symptoms

Interventions

Group 1: Patients wear a seizure detector, a Samsung Galaxy-5, and use 2 apps (STEADY app and Monikit app) at different time points.

Sponsors

Uniklinik RWTH Aachen
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Patients aged = 18 years of age 2. Patients are capable of consent themselves and/or have a legal guardian 3. The patients themselves use their own Android smartphones or consent to switching to a study-related Android smartphone at the test center. The Android smartphone must have at least Android version 6 of the operating system. 4. Diagnosed focal or generalized epilepsy with depressive symptoms determined with the BDI-2 (= 9 points) 5. There is a current treatment in the video-EEG monitoring unit of at least 24 hours

Exclusion criteria

Exclusion criteria: 1. There is currently an acute self-endangerment (one month before inclusion). 2. There is a lifetime diagnosis of a psychotic illness (every diagnosis according to DRG F20.X), every bipolar illness (F31.X), every borderline personality disorder 3. In the case of a lifetime diagnosis of substance abuse: in stable remission (at least 6 months) 4. Patients have a cardiac pacemaker or other implanted device (eg, VNS, ICD) 5. Patients have a known or suspected allergy to the materials of the device used or to the electrodes used. 6. Patients who are currently pregnant. This fact is recorded during anamnesis.

Design outcomes

Primary

MeasureTime frame
The primary endpoint is "Association between seizure frequency and depressive symptoms as measured by PHQ-9 and BDI-II".

Secondary

MeasureTime frame
The secondary endpoint is parameters such as sleep, step count, exercise, and voice modulation predict the individual extent of depressive symptoms.

Countries

Germany

Contacts

Public ContactYvonne Weber

Uniklinik RWTH Aachen

yweber@ukaachen.de+49 0241 80 85829

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026